A conversation about University of Chicago's clinical trial testing Eledon's tegoprubart
Breakthrough T1D CEO Aaron Kowalski, Ph.D., sits down for a conversation with Katie Beth Hand, a participant in the University of Chicago's clinical trial testing Eledon's tegoprubart. Tegoprubart is used as an alternative to standard immunosuppressants to help prevent transplanted islet cells from rejection in people with type 1 diabetes (T1D). Learn more about participating in clinical trials at: https://www.breakthrought1d.org/clini....
▶︎
The Islet Cell Act & Eledon Trial - Today's T1D Cure Research Explained
▶︎
Type 1 Diabetes: The Third Wheel
▶︎
Mid-Year Mission Update
▶︎
Living with Cervical Dystonia
▶︎
Why Lifting LESS Builds More Muscle After 60
▶︎
Nearly Cured of Type 1 Diabetes: One Woman’s Journey in the Eledon Trial
▶︎
Virginia Emergency Physicians Replaced By Private Equity
▶︎
Using Pig Cells to Cure Type 1 Diabetes Without Immunosuppression
▶︎
MyFriendBen - From Start to Finish: Navigating Benefits in a Changing Landscape
▶︎
Mid-Year Mission Update 📱
▶︎
AI Is Creating A Rare Opportunity For Investors. How Jim Roppel Is Playing It. | Investing With IBD
▶︎
Meet Dr. William Gradishar: Yerbba's New Breast Oncologist
▶︎
The Most Exciting Month of Medical Breakthroughs in Years | Plain English
▶︎
Living with Type 1 Diabetes: Mental Health and Mindfulness
▶︎
40% of Middle Managers Have Never Received Training (with Emma Rose Connolly)
▶︎
Why Software Implementations Reveal the Truth About Your DSO
▶︎
Is This the Beginning of the End for Type 1 Diabetes? ft. Katie Beth, Eledon Trial Patient-9
▶︎
Who Is the U.S. Health System Really For? | NYT Opinion
▶︎
A Discussion on the Potential Reclassification of Deceased Donor Islets from Drugs to Organs
▶︎